Newsroom

May 11, 2026

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

Oral presentations feature CAPLYTA® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms 18 abstracts highlight J&J’s leadership and deep portfolio in neuropsychiatry at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings

Innovative Medicine

May 7, 2026

Johnson & Johnson launches Generation Fine, a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don’t believe antidepressants will help them reach remission Campaign draws on expertise of Mental Health America and elevates the voices of leading mental health advocates, including Kyle Long, television studio analyst, retired National Football League (NFL) player

Innovative Medicine

May 4, 2026

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

CAPLYTA® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the secondary endpoints for the adjunctive MDD therapies evaluated, CAPLYTA® demonstrated no weight gain compared to placebo plus antidepressant therapy Featured in a late-breaking presentation at the 2026 NEI Spring Congress, analysis provides indirect comparisons to help inform treatment decisions in the absence of head-to-head clinical trials

Innovative Medicine

April 27, 2026

FDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia

CAPLYTA® reduced relapse risk by 63 percent, with 84 percent of patients with schizophrenia relapse-free over six months Demonstrating long-term stability and a well-established safety profile consistent with previous CAPLYTA® studies

Innovative Medicine

April 22, 2026

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained minimal symptom expression (MSE) experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 study EPIC, the first head-to-head study of IMAAVY versus another FcRn blocker in generalized myasthenia gravis, is now enrolling participants

Innovative Medicine

January 16, 2026

New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder

CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data from two Phase 3 studies 65% of patients reached remission with CAPLYTA®, with 43% achieving sustained relief from symptoms, in a six-month open-label extension safety study Newly approved as an adjunctive for major depressive disorder, CAPLYTA® supports the ultimate treatment goal of remission with robust short-term data and long-term open-label safety data

Newsroom

Press releases

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

Johnson & Johnson launches Generation Fine, a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

FDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder

You are now leaving jnj.com/innovativemedicine

Search Results

No Results

Newsroom

Press releases

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

Johnson & Johnson launches Generation Fine, a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

FDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder

You are now leaving jnj.com/innovativemedicine